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Abstract:   20 
For clinical isolates of bovine Mannheimia haemolytica and Pasteurella multocida, this study 21 
reports: minimum inhibitory concentration (MIC) differences for tetracycline, oxytetracycline 22 
and doxycycline between cation-adjusted Mueller Hinton broth (CAMHB), foetal bovine 23 
serum (FBS) and Roswell Park Memorial Institute (RPMI) medium. MICs were determined 24 
according to CLSI standards and additionally using five overlapping sets of two-fold 25 
dilutions. Matrix effect: (a) free drug MICs and minimum bactericidal concentrations (MBC) 26 
for all drugs were significantly higher in FBS than in CAMHB for both pathogens (p < 0.001); 27 
(b) MICs and MBCs were higher for CAMHB and FBS compared to RPMI for P. multocida 28 
only. Net growth rate for P. multocida in CAMHB was significantly slower than in FBS and 29 
higher than in RPMI, correlating to MIC and MBC ranking. Drug effect: doxycycline MICs 30 
and MBCs were significantly lower (p < 0.001) in both CAMHB and FBS than tetracycline 31 
and oxytetracycline for both pathogens. Only for M. haemolytica were oxytetracycline MIC 32 
and MBC significantly lower than tetracycline, precluding the use of tetracycline to predict 33 
oxytetracycline susceptibility in this species. Determining potencies of tetracyclines in a 34 
physiological medium, such as FBS, is proposed, when the objective is correlation with 35 
pharmacokinetic data for dosage determination. 36 
 37 
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  40 
Introduction:  41 
The bovine pathogens Mannheimia haemolytica and Pasteurella multocida have been 42 
specifically linked to cases of bovine calf pneumonia (Davies et al., 2004; Griffin et al., 2010; 43 
Welsh et al., 2004). The high prevalence of these infections has necessitated the 44 
widespread use in veterinary medicine of tetracyclines, especially oxytetracycline and 45 
doxycycline. Susceptibility to these AMDs is most commonly measured using the minimum 46 
inhibitory concentration (MIC). Standard methodologies have been published by the 47 
European Union Committee on Antimicrobial Susceptibility Testing (EUCAST) and the 48 
Clinical Laboratory Standards Institute (CLSI). Adoption of these procedures ensures inter-49 
laboratory and international dissemination of generated data to common standards (Papich, 50 
2014).  51 
Although useful for ensuring comparability of data between laboratories, the standardised 52 
methods have limitations of accuracy. As discussed by Mouton et al. (2018), the use of MIC 53 
based on a single MIC determination is not sufficient for purposes of dosage determination 54 
when combined with PK/PD data. First, as MICs are based on a two-fold dilution series, the 55 
a priori inaccuracy may approach 100% for a single isolate. In the current  study, the 56 
inaccuracy was reduced to less than 20% by use of  five overlapping two-fold dilutions series 57 
(Aliabadi and Lees, 2001; Sidhu et al., 2011). Secondly, the physiological relevance of in 58 
vitro methods using artificial media, such as cation-adjusted Mueller-Hinton broth (CAMHB), 59 
has been questioned for some drug classes, including tetracyclines and macrolides. For 60 
these classes, MICs for most pathogens are markedly dependent on the growth medium 61 
(Brentnall et al., 2012; Buyck et al., 2012; Dorey et al., 2016; Lees et al., 2015, 2016; Toutain 62 
et al., 2017). For the same drug and similar testing conditions (inoculum size and incubation 63 
time), the differences in MIC (on a free-concentration basis) between the afore-mentioned 64 
media could be related solely to rates of  bacterial growth and death in each medium 65 
(Mouton and Vinks, 2005).  66 
Dalhoff (2018) commented that the impact of media protein on AMD activity is multi-faceted, 67 
influencing cell permeability to the AMD and growth of the organism. Using physiological 68 
fluids, such as foetal bovine serum (FBS) and inflammatory exudate or an equivalent 69 
designed for eukaryotic cell culture, such as Roswell Park Memorial Institute (RPMI) 70 
medium, may provide useful, alternatives to those broths, which are formulated not to mimic 71 
conditions in vivo but to facilitate bacterial growth in vitro (Buyck et al., 2012).  72 
When established clinical breakpoints are not available for a given AMD, those available for 73 
structurally related members of the same drug class have been used. For example, when 74 
information on the efficacy of oxytetracycline is not available, tetracycline has been used to 75 
represent other drugs of the same class. As culture sensitivity testing panels may only 76 
include tetracycline and/or doxycycline, this study compared MICs and MBCs of tetracycline, 77 
oxytetracycline and doxycycline for two calf pneumonia pathogens.  78 
The objective was to identify, for six isolates each of M. haemolytica and P. multocida in 79 
three matrices (CAHMB, FBS and RPMI), if the growth medium, based on comparative static 80 
growth curves, impacts on susceptibility and MIC. MICs and MBCs were determined using 81 
two-fold standardised dilution series (Clinical and Laboratory Standards Institute CLSI, 82 
2013) but also using five overlapping two-fold dilution series. A secondary objective was to 83 
identify whether  usingfive overlapping two-fold dilution series impacts on tetracycline as an 84 
appropriate susceptibility benchmark for oxytetracycline. 85 
  86 
Materials and Methods  87 
Selection and storage of bacterial strains 88 
Six strains each of M. haemolytica and P. multocida, previously shown to grow 89 
logarithmically in MHB and FBS, were recovered from -70oC storage (medium 90 
glycerol:milk:water, 20:10:70). These strains were clinical isolates derived from non-related 91 
cases of calf pneumonia within the UK; they had been used in a previous study and were 92 
known to be sensitive to oxytetracycline (Lees et al., 2015). Strains were stored at -70oC in 93 
brain heart infusion (BHI) broth containing 25% glycerol for the duration of the study.  94 
 95 
Culture methods 96 
Bacteria were cultured in BHI broth or CAMHB (CM0405, Oxoid, UK) or as static cultures 97 
on BHI agar (1.5% bacteriological agar [LP0011, Oxoid, UK]) or Mueller-Hinton agar 98 
(CM0337, Oxoid, UK); all were prepared according to the manufacturer’s guidelines, unless 99 
otherwise stated.  Agar cultures were incubated statically (HeraCell incubator, Heraeus, UK) 100 
and broth cultures were incubated with shaking at 150 rpm (Incu-shaker mini, Benchmark, 101 
UK), both at 37oC.   102 
 103 
Antimicrobial drug preparation and storage 104 
Stock drug solutions of tetracycline hydrochloride (#10460264, Fisher Scientific, UK) and 105 
oxytetracycline hydrochloride (#O5875, Sigma, UK) were prepared to concentrations of 10 106 
mg/mL in deionized water and doxycycline monohydrate (#15580594, Fisher scientific, UK) 107 
was prepared to 2 mg/mL in ethanol. Concentrations refer to base molecules. All solutions 108 
were filter sterilised using a 0.22 µm syringe filter. Weighing of drug powders was adjusted 109 
according to the potency calculations outlined in the CLSI guidelines (CLSI, 2013). Aliquots 110 
of 1 mL were stored in amber microcentrifuge tubes at – 20oC.   111 
 112 
Determination of MIC and MBC 113 
MICs were determined in accordance with CLSI standards (CLSI, 2013). The CLSI two-fold 114 
dilution series (0.0625 – 32 µg/mL) method was adapted; four additional overlapping dilution 115 
series (0.04375 – 22.4, 0.05 – 25.6, 0.05625 – 28.8, 0.0625 – 32, 0.075 – 38.4 µg/mL) were 116 
used to improve the accuracy of MIC and MBC measurements (Sidhu et al,. 2011). Dilutions 117 
of AMDs were prepared in broths (CAMHB and RPMI) or FBS at the aforementioned 118 
concentrations. In FBS, free drug fractions were calculated from protein binding data, using 119 
values of 31% for tetracycline (Ziv and Sulman, 1972; Riviere and Papich, 2009), 50% for 120 
oxytetracycline (Brentnall et al., 2013; Pilloud, 1973) and 92% for doxycycline (Riviere and 121 
Papich, 2018). For RPMI, MICs could be determined for P. multocida only after 122 
supplementation with 0.1 M phosphate, pH 6.8, according to the method previously 123 
described (Sun and Clinkenbeard, 1998). M. haemolytica MIC could not be determined in 124 
RPMI, as it could not be grown without adding a proportion of FBS of at least 0.1%. MIC 125 
tests were repeated a minimum of three times, on separate days, and mean MIC values 126 
were calculated. 127 
MBC was determined by a spot-plate method. A 10 µL sample from each well, equal to and 128 
exceeding the MIC, was spotted onto a Mueller-Hinton agar plate and incubated overnight 129 
at 37oC. Plates were inspected for growth and MBC was recorded as the point at which no 130 
growth occurred. 131 
 132 
  133 
Growth curves:  134 
Static growth curves of P. multocida were performed in each of the three growth media. 135 
Each strain was grown overnight (14-16h) in BHI broth at high-density logarithmic growth. A 136 
100 µL aliquot of the suspension was transferred into 5 mL of either FBS, CAMHB or RPMI 137 
(supplemented with 0.1 M phosphate, pH 6.8). Each inoculated medium was then incubated 138 
at 37oC in a shaking incubator at 150 rpm. Samples were taken at 0, 1, 2, 4, 8, 24 h and 139 
viable cell counts performed using a spot-plate method, in which a ten-fold dilution series 140 
was prepared and three 10 µL drops were spotted onto a Mueller-Hinton agar plate. 141 
Following drying and overnight incubation, colonies were counted and counts adjusted for 142 
the dilution factor.  143 
 144 
Statistical analyses 145 
MIC and MBC are reported as geometric means and standard deviations. Concentration 146 
data were transformed to compensate for the doubling dilution series by ln(2) transformation 147 
prior to statistical analysis, and presented graphically on an ordinate axis with a ln(2) base 148 
(2-fold increments). Differences between MIC and MBC values were identified following 149 
analysis of variance (ANOVA) and, when appropriate, Tukey post-hoc analysis of 150 
significance for each of the variables using the software R (open source (https://www.r-151 
project.org/). Data were also converted to reflect the traditional testing approach, using 2-152 
fold dilution series (0.25, 0.5, 1, 2, 4, 8, 16, 32 µg/mL) and subjected to the same statistical 153 
analysis to determine whether any significant differences would have been detected, had 154 
overlapping dilutions not been used.  155 
Growth rates were evaluated by comparing log10 bacterial counts for each medium at each 156 
time point and testing the effect of time x medium interaction (linear mixed effect model with 157 
Tukey post-hoc analysis in R). 158 
  159 
Results 160 
Matrix effect 161 
Following correction of FBS values for protein binding, there were highly significant 162 
differences between media in geometric mean MIC and MBC values for P. multocida for all 163 
drugs, tetracycline, oxytetracycline and doxycycline (Table 1, Fig.1). Compared to MICs 164 
determined in CAMHB (the standard CLSI-proposed medium for determination of MIC for 165 
P. multocida) MICs in FBS were significantly higher with ratios (FBS:CAMHB)  of 6.7:1, 7.0:1 166 
and 1.3:1 for tetracycline, oxytetracycline and doxycycline, respectively. For tetracycline and 167 
oxytetracycline, MICs in RPMI were significantly lower than those determined in both FBS 168 
and CAMHB. In RPMI, MICs for tetracycline were 5.4x, and for oxytetracycline 3.4x lower 169 
than in CAMHB. Consequently, ratios FBS:RPMI, of 36.1:1 for tetracycline and 23.8:1 170 
oxytetracycline were even higher than FBS:CAMHB ratios.    171 
Inter-strain variability in MBCs was greater than MIC variability for each drug in each 172 
medium. However, the order of potency (most to least) for MBCs was the same as MICs, 173 
namely RPMI>CAMHB>FBS for all drugs, and MBC ratios FBS:CAMHB and FBS:RPMI 174 
exceeded unity but were smaller in magnitude than corresponding MIC ratios. 175 
For M. haemolytica and all tetracyclines, MICs were significantly higher in FBS (corrected 176 
for protein binding) than in CAMHB. Thus, FBS:CAMHB ratios were 10.5:1, 7.7:1, and 1.7:1, 177 
respectively, for tetracycline, oxytetracycline and doxycycline. As with P. multocida, there 178 
was greater inter-strain variability in MBCs compared to MICs. However, MBCs were again 179 
higher in FBS compared to CAMHB for tetracycline and oxytetracycline. In summary, for 180 
both pathogens, the growth medium exerted a highly significant (p < 0.001) impact on MICs 181 
and MBCs for all drugs (Figure 1).  182 
Influence of matrix on bacterial growth rate 183 
The rate and magnitude of bacterial growth in the absence of drugs was determined using 184 
static growth curves. Comparison of the three media indicated that the support of growth of 185 
six isolates of P. multocida was consistently higher in FBS compared with CAMHB (Figure 186 
2).  Thus, bacterial counts were significantly higher from 8 to 24 h (p < 0.01) for FBS. RPMI 187 
(supplemented with 0.1M phosphate, pH 6.8) was relatively poor in supporting the growth 188 
of P. multocida, compared with both FBS and CAMHB. Bacterial counts were significantly 189 
higher for the latter two media than with RPMI at all time points after inoculation (p < 0.05). 190 
Therefore, the medium providing the highest bacterial growth rate (FBS) had highest MIC 191 
and MBC values for these tetracyclines, whilst the medium with lowest growth rate (RPMI) 192 
had the lowest MICs and MBCs.  193 
Method effect 194 
Differences in drug potency/efficacy between tetracycline, oxytetracycline and doxycycline 195 
were explored by comparing MICs and MBCs obtained in CAMHB, FBS and RPMI using 196 
five overlapping sets of doubling dilutions (Fig. 3). Using this adapted method, for P. 197 
multocida, in RPMI only, tetracycline MICs and MBCs were significantly lower (P < 0.001) 198 
than those for oxytetracycline. Both CAMHB and FBS showed no significant difference 199 
between MICs for tetracycline and oxytetracycline. For M. haemolytica, tetracycline MICs, 200 
determined using five overlapping sets of doubling dilutions in both CAMHB and FBS, were 201 
significantly higher (p < 0.001) than those for oxytetracycline. MBC values were again 202 
significantly higher (p < 0.001) for tetracycline than for oxytetracycline in FBS. Doxycycline 203 
MICs and MBCs were significantly lower (p < 0.001) across both strains and all media.  204 
 205 
When MICs were determined using the traditional 2-fold dilution series (0.25, 0.5, 1, 2, 4, 8, 206 
16, 32 µg/mL) and applying the same statistical analyses (Supplementary Table and Figures 207 
S1 and S2), there were no significant differences between the MICs for tetracycline and 208 
oxytetracycline against M. haemolytica in CAMHB, whereas the 5-dilution series revealed 209 
statistically significant differences between all three drugs. For P. multocida, however, the 210 
2-fold dilution series gave the same conclusion as the 5-overlapping dilution series, namely 211 
that doxycycline was significantly more potent than tetracycline and oxytetracycline, whilst 212 
tetracycline and oxytetracycline did not differ significantly. 213 
Discussion:  214 
This study evaluated if growth matrix exerted a significant effect on MICs and MBCs for 215 
three tetracyclines against the bovine pathogens, P. multocida and M. haemolytica and, if 216 
so, by what underlying mechanism. A second objective was to identify if, using a method of 217 
increased accuracy for MIC determination, namely five-overlapping dilution series, 218 
tetracycline MICs are indicative of those for oxytetracycline.  219 
Comparison of FBS and CAMHB for MIC and MBC determination 220 
The literature cites many examples of differences in MIC measured, on the one hand, in 221 
broths using the internationally recognised CLSI or EUCAST standards and, on the other, 222 
determinations made in physiological fluids such as serum or eukaryotic media such as 223 
RPMI. Brentnall et al. (2012, 2013) determined oxytetracycline MIC in calf serum against a 224 
single isolate of M. haemolytica. They reported a six-fold higher serum MIC than in broth. 225 
These studies were confirmed and extended to six bovine isolates each of both M. 226 
haemolytica and P. multocida (Lees , 2016). Increased MIC values of oxytetracycline with 227 
serum:MHB ratios of 25.2:1 and 27.4:1, respectively, before correction for protein binding, 228 
and ratios of the order of 6-8:1 for free drug concentration were obtained. Subsequently  229 
Lees et al. (2017) reported a free fraction serum MIC:broth ratio for oxytetracycline against 230 
P. multocida of pig origin of 6.30:1.These data are corroborated by the results of this study.  231 
Differences in MIC between serum and broths are not limited to P. multocida and M. 232 
haemolytica or to calf and pig pathogens. Comparing MICs for a range of tetracyclines in 233 
broth and 50% broth: 50% serum (both mouse and human serum) for S. pneumoniae and 234 
S. aureus revealed increased MICs in the serum:broth mixed matrix compared with broth 235 
(Honeyman et al., 2015).For 12 tetracyclines and 10 strains of S. aureus, increased MICs  236 
were obtained in the presence of serum and, for seven of  these compounds, the increase 237 
was in the range of 8- to 128-fold. Honeyman et al. (2015) did not correct for protein binding 238 
in their study but, as they explored multiple tetracyclines under the same conditions, if 239 
protein binding were the only influencing factor it would be predicted that MIC proportional 240 
differences would be  obtained consistently. They reported variability in MIC ratios between 241 
organisms and between drugs, demonstrating unequivocally that factors other than protein 242 
binding impact markedly on numerical values of MIC.  243 
Matrix-dependent factors influence MICs either through direct interaction with the AMD or 244 
indirectly through an influence on microorganism growth rate . Indeed, using the minimal 245 
model of MIC, as reported by Mouton and Vinks (2005), growth rate is a major factor 246 
influencing the numerical value of MIC, when other conditions are equal. A recent study by 247 
Dorey and Lees (2017) quantified 14 biochemical constituents in calf serum and CAMHB 248 
and, despite considerable variation in each, none of the differences explained the substantial 249 
differences in MIC. Barbour (2014) suggests that these factors may differ between subjects 250 
of differing ages and health status, further impacting on the matrix effect. The present data 251 
substantiate earlier findings that unidentified factors affecting bacterial growth rate exert 252 
significant effects on  MIC.  253 
Many studies have shown that inoculum size can exert profound effects on MIC (Dorey et 254 
al., 2016, 2017; Illambas et al., 2013). Although the EUCAST and CLSI standards dictate a 255 
starting inoculum count, there is limited literature exploring the effect of growth rate and the 256 
bacterial burden over time.  257 
The strains selected for this study were previously shown to grow logarithmically in both 258 
FBS and CAMHB. However, comparing growth curves in the absence of AMD in this study, 259 
maximal viable cell counts after 8 and 24h incubation were higher for FBS than CAMHB, 260 
which in turn was higher than RPMI. The capacity to support bacterial growth, correlating 261 
with numerical MIC values, suggests that bacterial growth rate, and therefore bacterial 262 
burden achieved,  is one and possibly the principal factor determining matrix MIC and MBC 263 
differences. This might be attributable to the higher challenge to drug activity with higher 264 
bacterial counts with FBS and, conversely, the lower bacterial counts with RPMI providing 265 
a lesser challenge to drug inhibitory action.  266 
Whatever the underlying cause of matrix-based potency differences, the present data 267 
unequivocally indicate that other matrix-specific factors influence measured MICs, possibly 268 
through differences in bacterial growth or death rates. Mouton and Vinks (2005) presented 269 
an equation for calculation of MIC, based on several input factors, including growth and kill 270 
rates and this model is consistent with the present results, indicating that reducing the net 271 
growth rate decreases correlatively with the MIC, other factors being equal.  272 
Tetracycline as a surrogate for susceptibility testing of oxytetracycline 273 
The standards for determination of MIC and MBC rely on the unproven assumption that, in 274 
the absence of defined breakpoints for a given drug, other drugs within the same class will 275 
have equal potency. This assumption should be questioned; it is a fundamental principle of 276 
pharmacology that two agonist (or antagonist) drugs of differing chemical structures (even 277 
very minor differences) acting at the same site (on the same receptor or enzyme) will almost 278 
invariably have differing potencies. MICs may differ by several orders of magnitude, as a 279 
consequence of differing pharmacodynamic factors; including efficacy (in vitro killing rate), 280 
potency (differing concentrations to achieve a given in vitro killing rate) and sensitivity of the 281 
concentration/effect relationship. Moreover, as previously discussed, other biochemical 282 
factors that are matrix dependent may also be consequential, even when the AMDs share 283 
similar antimicrobial actions and physico-chemical properties. As MIC breakpoints are used 284 
in conjunction with pharmacokinetic data to predict dosage regimens, it is essential to allow 285 
for pharmacodynamic as well as pharmacokinetic differences between drugs of a single 286 
class. This study investigated whether tetracycline, the prototypic drug of the class, can be 287 
used as a surrogate representative for oxytetracycline. 288 
This study evaluated the impact of using five overlapping 2- fold dilution series, compared 289 
to the widely used single 2-fold dilution series. For M. haemolytica, analysis of the data by 290 
the traditional methodology indicated no significant potency differences between the three 291 
drugs, when tested in CAMHB. In contrast, the data obtained from the five overlapping 2-292 
fold dilution series revealed small but significant differences between tetracycline and 293 
oxytetracycline. This implies that standard testing methods may not be sufficiently sensitive 294 
to identify small but nevertheless significant potency differences between AMDs of the same 295 
class for some bacterial species. Therefore, it is possible that the use of tetracycline as a 296 
surrogate for oxytetracycline is inappropriate, due to the limited discriminatory power of the 297 
susceptibility assay (single 2-fold dilution series). However, this was not always the case. 298 
For P. multocida, in both the five overlapping dilution series and the single 2-fold dilution 299 
series, it is concluded that tetracycline and oxytetracycline did not differ significantly in 300 
potency. 301 
In summary, the five overlapping 2-fold dilution series provides a more accurate MIC 302 
determination for single or small numbers of isolates. Additionally, it provides a method for 303 
identifying minor differences in drug potency that would otherwise not be revealed using 304 
standard methods. The assumption that tetracycline is representative of oxytetracycline 305 
does not hold true for M. haemolytica in a biologically relevant context.   It is conluded that 306 
prediction of dosages for clinical use, based on traditional in vitro MIC and MBC 307 
measurements, is insufficiently accurate and might therefore potentially lead to sub-optimal 308 
dosing regimens. To ensure relevance and accuracy of MIC measurements for clinical 309 
therapeutic decisions, it is concluded that they should be determined in physiological fluids 310 
such as FBS. Whilst FBS may not be representative of all biological fluids (e.g. interstitial 311 
fluid or inflammatory exudate) it is likely to be more so than CAMHB (Brentnall et al., 2012, 312 
2013; Dorey and Lees 2017; Dorey et al., 2017).  313 
An important challenge, arising from the present study, is how to standardise estimates of 314 
AMD potency (MIC and MBC) in biological fluids such as FBS. It is suggested that future 315 
studies should examine the reproducibility of MIC / MBC testing with different FBS batches, 316 
possibly from different animal breeds, animals of differing age and in healthy versus 317 
diseased animals. The use of FBS is one means of ensuring that serum is not already primed 318 
for the organisms being studied, as antibodies are not transferred to the foetus, due to their 319 
inhibition by the synepitheliochorial placenta (Borghesi et al., 2014). However,  a study by 320 
Reiche et al. (1980), demonstrated that the degree of protein binding of chloramphenicol 321 
was greater in adult cattle compared to calves, highlighting an important consideration when 322 
performing studies in FBS. Moreover, protein concentrations and various co-factors may 323 
vary in FBS obtained from different sources, e.g. different breeds or even countries. 324 
Nevertheless, if the level of variation is known, it can be accounted for. A next step can then 325 
be more precise and accurate determination of pharmacodynamic indices in biologically 326 
relevant fluids and their application in dosage estimation. Whilst these variations must be 327 
determined experimentally, they are likely to be much smaller than the marked differences 328 
between FBS and CAMHB reported in thisstudy.  329 
The use of the five-overlapping 2-fold dilution series in this study limits the potential for 330 
inaccuracy in MIC measurement to no more than 20% for each isolate. The small number 331 
of isolates used, six for each organism, requires confirmation using a larger number of wild-332 
type environmental isolates; future studies will seek to expand on this facet of the work. 333 
Conclusions:  334 
The results presented in this paper indicate a significant effect of growth matrix on MICs and 335 
MBCs of three tetracyclines  for two cattle pathogens. These findings indicate that the 336 
determination of in vitro pharmacodynamic values, and their subsequent application to 337 
dosage regimen prediction, may require the use of a physiologically relevant growth medium 338 
to more accurately predict drug action in vivo. The sole reliance on broths as growth media 339 
may, for the tetracycline class of drugs, lead to sub-optimal therapeutic drug choice, reduced 340 
clinical efficacy and increased resistance selection. Further studies are now required to 341 
further optimise the use of alternative growth matrices for determination of in vitro 342 
pharmacodynamics for this drug class. 343 
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  452 
Table 1:  453 
Geometric mean free drug concentration (µg/mL) MIC, MBC and standard deviation (SD, n=6) for tetracycline, oxytetracycline and 454 
doxycycline, measured in CAMHB, FBS and RPMI for P. multocida and M. haemolytica. 455 
N/A= not applicable 456 
457 
P. multocida Tetracycline Oxytetracycline Doxycycline 
Medium MIC MBC MIC MBC MIC MBC 
CAMHB 0.38 (0.15) 1.14 (1.07) 0.34 (0.11) 1.27 (0.85) 0.18 (0.13) 0.53 (0.45) 
FBS 2.53 (1.42) 4.95 (1.80) 2.38 (0.87) 3.21 (1.83) 0.24 (0.09) 0.54 (0.12) 
RPMI 0.07 (0.02) 0.22 (0.03) 0.10 (0.03) 0.35 (0.09) N/A N/A 
M. haemolytica Tetracycline Oxytetracycline Doxycycline 
Medium MIC MBC MIC MBC MIC MBC 
CAMHB 0.52 (0.18) 1.38 (0.80) 0.35 (0.14) 1.58 (0.99) 0.31 (0.05) 0.86 (0.47) 
FBS 5.46 (0.93) 9.38 (4.70) 2.68 (0.68) 5.03 (1.49) 0.53 (0.13) 0.99 (0.28) 
Figure 1. MIC and MBC comparisons between CAMHB, FBS and RPMI for tetracycline, oxytetracycline and doxycycline 458 
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) (µg/mL) for tetracycline, oxytetracycline and 459 
doxycycline, measured in CAMHB, FBS and RPMI for M. haemolytica and P. multocida after protein-binding correction. *P < 0.001 460 
(analysis of variance with Tukey post-hoc analysis). MIC and MBC determinations were based on 5-overlapping sets of doubling 461 
dilutions to increase accuracy. 462 
 463 
 464 
Figure 2. Comparative growth curves in CAMHB, FBS, and RPMI (supplemented with 0.1M phosphate, pH 6.8). 465 
Viable cell counts (CFU/mL) for each of six clinical isolates of P. multocida in the growth media CAMHB, FBS and RPMI 466 
(supplemented with 0.1M phosphate, pH 6.8). 467 
 468 
Figure 3. MIC and MBC comparisons for three tetracyclines in FBS, CAMHB, and RPMI. 469 
Mean MIC and MBC (µg/mL) for three tetracyclines (doxycycline, oxytetracycline and tetracycline) measured in CAMHB, FBS and 470 
RPMI for M. haemolytica and P. multocida after protein-binding correction. *P < 0.001 (analysis of variance with Tukey post-hoc 471 
analysis). N.S: No significant difference. MIC and MBC determinations were based on 5-overlapping sets of doubling dilutions to 472 
increase accuracy. 473 
  474 
Supplementary Data Table 1:   475 
Geometric mean free drug concentration (µg/mL) MIC, MBC and standard deviation (SD, n=6) for tetracycline, oxytetracycline and 476 
doxycycline, measured in CAMHB, FBS and RPMI for P. multocida and M. haemolytica using standard 2-fold dilution series. 477 
N/A= not applicable 478 
 479 
 480 
 481 
  482 
P. multocida Tetracycline Oxytetracycline Doxycycline 
Medium MIC MBC MIC MBC MIC MBC 
CAMHB 0.48 (0.2) 1.33 (1.22) 0.45 (0.10) 1.63 (1.11) 0.22 (0.13) 0.68 (0.59) 
FBS 3.35 (1.69) 6.50 (3.09) 2.83 (1.03) 5.42 (2.05) 0.32 (0.17) 0.69 (0.21) 
RPMI 0.08 (0.03) 0.26 (0.06) 0.14 (0.06) 0.41 (0.12) N/A N/A 
M. haemolytica Tetracycline Oxytetracycline Doxycycline 
Medium MIC MBC MIC MBC MIC MBC 
CAMHB 0.58 (0.21) 2.00 (1.80) 0.46 (0.21) 2.30 (1.35) 0.41 (0.12) 1.12 (0.52) 
FBS 6.95 (2.68) 13.54 (5.19) 3.85 (1.19) 6.60 (2.93) 0.67 (0.23) 1.44 (0.49) 
Supplementary Figure S1. MIC and MBC comparisons between CAMHB, FBS and RPMI for tetracycline, oxytetracycline 483 
and doxycycline 484 
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for tetracycline, oxytetracycline and 485 
doxycycline, measured in CAMHB, FBS and RPMI for M. haemolytica and P. multocida using standard 2-fold dilution series after 486 
protein-binding correction. *P < 0.001 (analysis of variance with Tukey post-hoc analysis). 487 
 488 
 489 
Supplementary Figure S2. MIC and MBC comparisons for three tetracyclines in FBS, CAMHB, and RPMI. 490 
Mean MIC and MBC for three tetracyclines (doxycycline, oxytetracycline and tetracycline) measured in CAMHB, FBS and RPMI for 491 
M. haemolytica and P. multocida using standard 2-fold dilutions series after protein-binding correction. *P < 0.001 (analysis of 492 
variance with Tukey post-hoc analysis). N.S: No significant difference.  493 
  494 
Supplementary Table 2:  495 
Raw data: MIC and MBC measurements in CAMHB and FBS measured as total and free 496 
concentrations.  497 
 498 
Media Test Drug Strain Concentration 
(µg/ml) 
Free concentration 
(µg/ml) 
CAMHB MIC Tetracycline P.mult_3722 0.45 0.45 
CAMHB MIC Tetracycline P.mult_3722 0.45 0.45 
CAMHB MIC Tetracycline P.mult_3722 0.5 0.5 
CAMHB MIC Oxytetracycline P.mult_3722 0.45 0.45 
CAMHB MIC Oxytetracycline P.mult_3722 0.45 0.45 
CAMHB MIC Oxytetracycline P.mult_3722 0.5 0.5 
CAMHB MIC Doxycycline P.mult_3722 0.45 0.45 
CAMHB MIC Doxycycline P.mult_3722 0.5 0.5 
CAMHB MIC Doxycycline P.mult_3722 0.45 0.45 
CAMHB MBC Tetracycline P.mult_3722 0.8 0.8 
CAMHB MBC Tetracycline P.mult_3722 0.8 0.8 
CAMHB MBC Tetracycline P.mult_3722 0.9 0.9 
CAMHB MBC Oxytetracycline P.mult_3722 0.9 0.9 
CAMHB MBC Oxytetracycline P.mult_3722 0.9 0.9 
CAMHB MBC Oxytetracycline P.mult_3722 0.9 0.9 
CAMHB MBC Doxycycline P.mult_3722 0.45 0.45 
CAMHB MBC Doxycycline P.mult_3722 0.6 0.6 
CAMHB MBC Doxycycline P.mult_3722 0.6 0.6 
CAMHB MIC Tetracycline P.mult_3920 0.45 0.45 
CAMHB MIC Tetracycline P.mult_3920 0.5 0.5 
CAMHB MIC Tetracycline P.mult_3920 0.5 0.5 
CAMHB MIC Oxytetracycline P.mult_3920 0.45 0.45 
CAMHB MIC Oxytetracycline P.mult_3920 0.45 0.45 
CAMHB MIC Oxytetracycline P.mult_3920 0.5 0.5 
CAMHB MIC Doxycycline P.mult_3920 0.25 0.25 
CAMHB MIC Doxycycline P.mult_3920 0.225 0.225 
CAMHB MIC Doxycycline P.mult_3920 0.2 0.2 
CAMHB MBC Tetracycline P.mult_3920 3.2 3.2 
CAMHB MBC Tetracycline P.mult_3920 3.2 3.2 
CAMHB MBC Tetracycline P.mult_3920 3.6 3.6 
CAMHB MBC Oxytetracycline P.mult_3920 2.8 2.8 
CAMHB MBC Oxytetracycline P.mult_3920 2.8 2.8 
CAMHB MBC Oxytetracycline P.mult_3920 3.6 3.6 
CAMHB MBC Doxycycline P.mult_3920 1.6 1.6 
CAMHB MBC Doxycycline P.mult_3920 1.6 1.6 
CAMHB MBC Doxycycline P.mult_3920 1.4 1.4 
CAMHB MIC Tetracycline P.mult_4072 0.175 0.175 
CAMHB MIC Tetracycline P.mult_4072 0.2 0.2 
CAMHB MIC Tetracycline P.mult_4072 0.175 0.175 
CAMHB MIC Oxytetracycline P.mult_4072 0.175 0.175 
CAMHB MIC Oxytetracycline P.mult_4072 0.2 0.2 
CAMHB MIC Oxytetracycline P.mult_4072 0.2 0.2 
CAMHB MIC Doxycycline P.mult_4072 0.0875 0.0875 
CAMHB MIC Doxycycline P.mult_4072 0.0875 0.0875 
CAMHB MIC Doxycycline P.mult_4072 0.1 0.1 
CAMHB MBC Tetracycline P.mult_4072 0.7 0.7 
CAMHB MBC Tetracycline P.mult_4072 0.7 0.7 
CAMHB MBC Tetracycline P.mult_4072 0.8 0.8 
CAMHB MBC Oxytetracycline P.mult_4072 0.9 0.9 
CAMHB MBC Oxytetracycline P.mult_4072 0.9 0.9 
CAMHB MBC Oxytetracycline P.mult_4072 
  
CAMHB MBC Doxycycline P.mult_4072 0.4 0.4 
CAMHB MBC Doxycycline P.mult_4072 0.4 0.4 
CAMHB MBC Doxycycline P.mult_4072 0.4 0.4 
CAMHB MIC Tetracycline P.mult_4096 0.35 0.35 
CAMHB MIC Tetracycline P.mult_4096 0.3 0.3 
CAMHB MIC Tetracycline P.mult_4096 0.3 0.3 
CAMHB MIC Oxytetracycline P.mult_4096 0.35 0.35 
CAMHB MIC Oxytetracycline P.mult_4096 0.35 0.35 
CAMHB MIC Oxytetracycline P.mult_4096 0.35 0.35 
CAMHB MIC Doxycycline P.mult_4096 0.15 0.15 
CAMHB MIC Doxycycline P.mult_4096 0.15 0.15 
CAMHB MIC Doxycycline P.mult_4096 0.15 0.15 
CAMHB MBC Tetracycline P.mult_4096 0.5 0.5 
CAMHB MBC Tetracycline P.mult_4096 0.5 0.5 
CAMHB MBC Tetracycline P.mult_4096 0.5 0.5 
CAMHB MBC Oxytetracycline P.mult_4096 0.7 0.7 
CAMHB MBC Oxytetracycline P.mult_4096 0.7 0.7 
CAMHB MBC Oxytetracycline P.mult_4096 1 1 
CAMHB MBC Doxycycline P.mult_4096 0.3 0.3 
CAMHB MBC Doxycycline P.mult_4096 0.25 0.25 
CAMHB MBC Doxycycline P.mult_4096 0.25 0.25 
CAMHB MIC Tetracycline P.mult_4121 0.4 0.4 
CAMHB MIC Tetracycline P.mult_4121 0.4 0.4 
CAMHB MIC Tetracycline P.mult_4121 0.3 0.3 
CAMHB MIC Oxytetracycline P.mult_4121 0.3 0.3 
CAMHB MIC Oxytetracycline P.mult_4121 0.3 0.3 
CAMHB MIC Oxytetracycline P.mult_4121 0.3 0.3 
CAMHB MIC Doxycycline P.mult_4121 0.125 0.125 
CAMHB MIC Doxycycline P.mult_4121 0.125 0.125 
CAMHB MIC Doxycycline P.mult_4121 0.125 0.125 
CAMHB MBC Tetracycline P.mult_4121 2 2 
CAMHB MBC Tetracycline P.mult_4121 2 2 
CAMHB MBC Tetracycline P.mult_4121 2 2 
CAMHB MBC Oxytetracycline P.mult_4121 1.6 1.6 
CAMHB MBC Oxytetracycline P.mult_4121 1.6 1.6 
CAMHB MBC Oxytetracycline P.mult_4121 1.6 1.6 
CAMHB MBC Doxycycline P.mult_4121 0.6 0.6 
CAMHB MBC Doxycycline P.mult_4121 0.6 0.6 
CAMHB MBC Doxycycline P.mult_4121 0.45 0.45 
CAMHB MIC Tetracycline P.mult_4323 0.5 0.5 
CAMHB MIC Tetracycline P.mult_4323 0.7 0.7 
CAMHB MIC Tetracycline P.mult_4323 0.7 0.7 
CAMHB MIC Oxytetracycline P.mult_4323 0.35 0.35 
CAMHB MIC Oxytetracycline P.mult_4323 0.4 0.4 
CAMHB MIC Oxytetracycline P.mult_4323 0.4 0.4 
CAMHB MIC Doxycycline P.mult_4323 0.225 0.225 
CAMHB MIC Doxycycline P.mult_4323 0.175 0.175 
CAMHB MIC Doxycycline P.mult_4323 0.175 0.175 
CAMHB MBC Tetracycline P.mult_4323 
  
CAMHB MBC Tetracycline P.mult_4323 1.2 1.2 
CAMHB MBC Tetracycline P.mult_4323 1 1 
CAMHB MBC Oxytetracycline P.mult_4323 1.2 1.2 
CAMHB MBC Oxytetracycline P.mult_4323 1.2 1.2 
CAMHB MBC Oxytetracycline P.mult_4323 1.6 1.6 
CAMHB MBC Doxycycline P.mult_4323 0.5 0.5 
CAMHB MBC Doxycycline P.mult_4323 0.45 0.45 
CAMHB MBC Doxycycline P.mult_4323 0.5 0.5 
CAMHB MIC Tetracycline M.haem_1056 0.6 0.6 
CAMHB MIC Tetracycline M.haem_1056 0.5 0.5 
CAMHB MIC Tetracycline M.haem_1056 0.5 0.5 
CAMHB MIC Oxytetracycline M.haem_1056 0.6 0.6 
CAMHB MIC Oxytetracycline M.haem_1056 0.5 0.5 
CAMHB MIC Oxytetracycline M.haem_1056 0.6 0.6 
CAMHB MIC Doxycycline M.haem_1056 0.3 0.3 
CAMHB MIC Doxycycline M.haem_1056 0.3 0.3 
CAMHB MIC Doxycycline M.haem_1056 0.3 0.3 
CAMHB MBC Tetracycline M.haem_1056 1.4 1.4 
CAMHB MBC Tetracycline M.haem_1056 1.2 1.2 
CAMHB MBC Tetracycline M.haem_1056 1.2 1.2 
CAMHB MBC Oxytetracycline M.haem_1056 2.8 2.8 
CAMHB MBC Oxytetracycline M.haem_1056 3.2 3.2 
CAMHB MBC Oxytetracycline M.haem_1056 3.6 3.6 
CAMHB MBC Doxycycline M.haem_1056 0.7 0.7 
CAMHB MBC Doxycycline M.haem_1056 0.6 0.6 
CAMHB MBC Doxycycline M.haem_1056 0.7 0.7 
CAMHB MIC Tetracycline M.haem_1250 0.45 0.45 
CAMHB MIC Tetracycline M.haem_1250 0.45 0.45 
CAMHB MIC Tetracycline M.haem_1250 0.45 0.45 
CAMHB MIC Oxytetracycline M.haem_1250 0.4 0.4 
CAMHB MIC Oxytetracycline M.haem_1250 0.4 0.4 
CAMHB MIC Oxytetracycline M.haem_1250 0.45 0.45 
CAMHB MIC Doxycycline M.haem_1250 0.35 0.35 
CAMHB MIC Doxycycline M.haem_1250 0.35 0.35 
CAMHB MIC Doxycycline M.haem_1250 0.35 0.35 
CAMHB MBC Tetracycline M.haem_1250 0.6 0.6 
CAMHB MBC Tetracycline M.haem_1250 0.7 0.7 
CAMHB MBC Tetracycline M.haem_1250 
  
CAMHB MBC Oxytetracycline M.haem_1250 0.6 0.6 
CAMHB MBC Oxytetracycline M.haem_1250 0.6 0.6 
CAMHB MBC Oxytetracycline M.haem_1250 0.6 0.6 
CAMHB MBC Doxycycline M.haem_1250 0.5 0.5 
CAMHB MBC Doxycycline M.haem_1250 0.6 0.6 
CAMHB MBC Doxycycline M.haem_1250 0.6 0.6 
CAMHB MIC Tetracycline M.haem_1978 1 1 
CAMHB MIC Tetracycline M.haem_1978 0.7 0.7 
CAMHB MIC Tetracycline M.haem_1978 1 1 
CAMHB MIC Oxytetracycline M.haem_1978 0.45 0.45 
CAMHB MIC Oxytetracycline M.haem_1978 0.45 0.45 
CAMHB MIC Oxytetracycline M.haem_1978 0.5 0.5 
CAMHB MIC Doxycycline M.haem_1978 0.4 0.4 
CAMHB MIC Doxycycline M.haem_1978 0.4 0.4 
CAMHB MIC Doxycycline M.haem_1978 0.4 0.4 
CAMHB MBC Tetracycline M.haem_1978 2 2 
CAMHB MBC Tetracycline M.haem_1978 4.7 4.7 
CAMHB MBC Tetracycline M.haem_1978 2 2 
CAMHB MBC Oxytetracycline M.haem_1978 2.4 2.4 
CAMHB MBC Oxytetracycline M.haem_1978 2.8 2.8 
CAMHB MBC Oxytetracycline M.haem_1978 2.8 2.8 
CAMHB MBC Doxycycline M.haem_1978 1.6 1.6 
CAMHB MBC Doxycycline M.haem_1978 1.8 1.8 
CAMHB MBC Doxycycline M.haem_1978 2 2 
CAMHB MIC Tetracycline M.haem_2008 0.45 0.45 
CAMHB MIC Tetracycline M.haem_2008 0.45 0.45 
CAMHB MIC Tetracycline M.haem_2008 0.45 0.45 
CAMHB MIC Oxytetracycline M.haem_2008 0.2 0.2 
CAMHB MIC Oxytetracycline M.haem_2008 0.175 0.175 
CAMHB MIC Oxytetracycline M.haem_2008 0.2 0.2 
CAMHB MIC Doxycycline M.haem_2008 0.35 0.35 
CAMHB MIC Doxycycline M.haem_2008 0.3 0.3 
CAMHB MIC Doxycycline M.haem_2008 0.35 0.35 
CAMHB MBC Tetracycline M.haem_2008 0.6 0.6 
CAMHB MBC Tetracycline M.haem_2008 
  
CAMHB MBC Tetracycline M.haem_2008 1 1 
CAMHB MBC Oxytetracycline M.haem_2008 0.7 0.7 
CAMHB MBC Oxytetracycline M.haem_2008 
  
CAMHB MBC Oxytetracycline M.haem_2008 1.2 1.2 
CAMHB MBC Doxycycline M.haem_2008 0.9 0.9 
CAMHB MBC Doxycycline M.haem_2008 0.8 0.8 
CAMHB MBC Doxycycline M.haem_2008 1 1 
CAMHB MIC Tetracycline M.haem_2059 0.45 0.45 
CAMHB MIC Tetracycline M.haem_2059 0.45 0.45 
CAMHB MIC Tetracycline M.haem_2059 0.45 0.45 
CAMHB MIC Oxytetracycline M.haem_2059 0.3 0.3 
CAMHB MIC Oxytetracycline M.haem_2059 0.3 0.3 
CAMHB MIC Oxytetracycline M.haem_2059 0.25 0.25 
CAMHB MIC Doxycycline M.haem_2059 0.25 0.25 
CAMHB MIC Doxycycline M.haem_2059 0.25 0.25 
CAMHB MIC Doxycycline M.haem_2059 0.35 0.35 
CAMHB MBC Tetracycline M.haem_2059 2.4 2.4 
CAMHB MBC Tetracycline M.haem_2059 
  
CAMHB MBC Tetracycline M.haem_2059 1.8 1.8 
CAMHB MBC Oxytetracycline M.haem_2059 1.6 1.6 
CAMHB MBC Oxytetracycline M.haem_2059 
  
CAMHB MBC Oxytetracycline M.haem_2059 1.6 1.6 
CAMHB MBC Doxycycline M.haem_2059 0.5 0.5 
CAMHB MBC Doxycycline M.haem_2059 0.6 0.6 
CAMHB MBC Doxycycline M.haem_2059 0.7 0.7 
CAMHB MIC Tetracycline M.haem_2563 0.45 0.45 
CAMHB MIC Tetracycline M.haem_2563 0.45 0.45 
CAMHB MIC Tetracycline M.haem_2563 0.45 0.45 
CAMHB MIC Oxytetracycline M.haem_2563 0.3 0.3 
CAMHB MIC Oxytetracycline M.haem_2563 0.3 0.3 
CAMHB MIC Oxytetracycline M.haem_2563 0.35 0.35 
CAMHB MIC Doxycycline M.haem_2563 0.25 0.25 
CAMHB MIC Doxycycline M.haem_2563 0.25 0.25 
CAMHB MIC Doxycycline M.haem_2563 0.25 0.25 
CAMHB MBC Tetracycline M.haem_2563 2.4 2.4 
CAMHB MBC Tetracycline M.haem_2563 1.8 1.8 
CAMHB MBC Tetracycline M.haem_2563 1.8 1.8 
CAMHB MBC Oxytetracycline M.haem_2563 1.8 1.8 
CAMHB MBC Oxytetracycline M.haem_2563 
  
CAMHB MBC Oxytetracycline M.haem_2563 2.4 2.4 
CAMHB MBC Doxycycline M.haem_2563 1.2 1.2 
CAMHB MBC Doxycycline M.haem_2563 1.2 1.2 
CAMHB MBC Doxycycline M.haem_2563 1 1 
FBS MIC Doxycycline P.mult_3722 3.6 0.288 
FBS MIC Doxycycline P.mult_3722 3.6 0.288 
FBS MIC Doxycycline P.mult_3722 4 0.32 
FBS MBC Doxycycline P.mult_3722 5.6 0.448 
FBS MBC Doxycycline P.mult_3722 5.6 0.448 
FBS MBC Doxycycline P.mult_3722 5.6 0.448 
FBS MIC Doxycycline P.mult_3920 2 0.16 
FBS MIC Doxycycline P.mult_3920 2.4 0.192 
FBS MIC Doxycycline P.mult_3920 2.8 0.224 
FBS MBC Doxycycline P.mult_3920 4.8 0.384 
FBS MBC Doxycycline P.mult_3920 5.6 0.448 
FBS MBC Doxycycline P.mult_3920 5.6 0.448 
FBS MIC Doxycycline P.mult_4072 1.4 0.112 
FBS MIC Doxycycline P.mult_4072 1.4 0.112 
FBS MIC Doxycycline P.mult_4072 1.6 0.128 
FBS MBC Doxycycline P.mult_4072 6.4 0.512 
FBS MBC Doxycycline P.mult_4072 5.6 0.448 
FBS MBC Doxycycline P.mult_4072 5.6 0.448 
FBS MIC Doxycycline P.mult_4096 4 0.32 
FBS MIC Doxycycline P.mult_4096 4.8 0.384 
FBS MIC Doxycycline P.mult_4096 4.8 0.384 
FBS MBC Doxycycline P.mult_4096 8 0.64 
FBS MBC Doxycycline P.mult_4096 8 0.64 
FBS MBC Doxycycline P.mult_4096 9.6 0.768 
FBS MIC Doxycycline P.mult_4121 4.8 0.384 
FBS MIC Doxycycline P.mult_4121 4.8 0.384 
FBS MIC Doxycycline P.mult_4121 3.6 0.288 
FBS MBC Doxycycline P.mult_4121 7.2 0.576 
FBS MBC Doxycycline P.mult_4121 7.2 0.576 
FBS MBC Doxycycline P.mult_4121 7.2 0.576 
FBS MIC Doxycycline P.mult_4323 3.2 0.256 
FBS MIC Doxycycline P.mult_4323 3.2 0.256 
FBS MIC Doxycycline P.mult_4323 2.8 0.224 
FBS MBC Doxycycline P.mult_4323 9.6 0.768 
FBS MBC Doxycycline P.mult_4323 8 0.64 
FBS MBC Doxycycline P.mult_4323 8 0.64 
FBS MIC Doxycycline M.haem_1056 6.4 0.512 
FBS MIC Doxycycline M.haem_1056 5.6 0.448 
FBS MIC Doxycycline M.haem_1056 5.6 0.448 
FBS MBC Doxycycline M.haem_1056 12.8 1.024 
FBS MBC Doxycycline M.haem_1056 12.8 1.024 
FBS MBC Doxycycline M.haem_1056 11.2 0.896 
FBS MIC Doxycycline M.haem_1250 9.6 0.768 
FBS MIC Doxycycline M.haem_1250 8 0.64 
FBS MIC Doxycycline M.haem_1250 8 0.64 
FBS MBC Doxycycline M.haem_1250 9.6 0.768 
FBS MBC Doxycycline M.haem_1250 9.6 0.768 
FBS MBC Doxycycline M.haem_1250 9.6 0.768 
FBS MIC Doxycycline M.haem_1978 8 0.64 
FBS MIC Doxycycline M.haem_1978 9.6 0.768 
FBS MIC Doxycycline M.haem_1978 8 0.64 
FBS MBC Doxycycline M.haem_1978 11.2 0.896 
FBS MBC Doxycycline M.haem_1978 9.6 0.768 
FBS MBC Doxycycline M.haem_1978 9.6 0.768 
FBS MIC Doxycycline M.haem_2008 5.6 0.448 
FBS MIC Doxycycline M.haem_2008 6.4 0.512 
FBS MIC Doxycycline M.haem_2008 5.6 0.448 
FBS MBC Doxycycline M.haem_2008 19.2 1.536 
FBS MBC Doxycycline M.haem_2008 19.2 1.536 
FBS MBC Doxycycline M.haem_2008 19.2 1.536 
FBS MIC Doxycycline M.haem_2059 7.2 0.576 
FBS MIC Doxycycline M.haem_2059 8 0.64 
FBS MIC Doxycycline M.haem_2059 8 0.64 
FBS MBC Doxycycline M.haem_2059 11.2 0.896 
FBS MBC Doxycycline M.haem_2059 11.2 0.896 
FBS MBC Doxycycline M.haem_2059 11.2 0.896 
FBS MIC Doxycycline M.haem_2563 6.4 0.512 
FBS MIC Doxycycline M.haem_2563 5.6 0.448 
FBS MIC Doxycycline M.haem_2563 2.8 0.224 
FBS MBC Doxycycline M.haem_2563 16 1.28 
FBS MBC Doxycycline M.haem_2563 16 1.28 
FBS MBC Doxycycline M.haem_2563 11.2 0.896 
FBS MIC Oxytetracycline P.mult_3722 4 2 
FBS MIC Oxytetracycline P.mult_3722 3.6 1.8 
FBS MIC Oxytetracycline P.mult_3722 3.6 1.8 
FBS MBC Oxytetracycline P.mult_3722 6.4 3.2 
FBS MBC Oxytetracycline P.mult_3722 7.2 3.6 
FBS MBC Oxytetracycline P.mult_3722 6.4 3.2 
FBS MIC Oxytetracycline P.mult_3920 4 2 
FBS MIC Oxytetracycline P.mult_3920 3.6 1.8 
FBS MIC Oxytetracycline P.mult_3920 2.8 1.4 
FBS MBC Oxytetracycline P.mult_3920 8 4 
FBS MBC Oxytetracycline P.mult_3920 8 4 
FBS MBC Oxytetracycline P.mult_3920 
 
0 
FBS MIC Oxytetracycline P.mult_4072 4 2 
FBS MIC Oxytetracycline P.mult_4072 3.6 1.8 
FBS MIC Oxytetracycline P.mult_4072 3.6 1.8 
FBS MBC Oxytetracycline P.mult_4072 6.4 3.2 
FBS MBC Oxytetracycline P.mult_4072 5.6 2.8 
FBS MBC Oxytetracycline P.mult_4072 6.4 3.2 
FBS MIC Oxytetracycline P.mult_4096 4.8 2.4 
FBS MIC Oxytetracycline P.mult_4096 4.8 2.4 
FBS MIC Oxytetracycline P.mult_4096 5.6 2.8 
FBS MBC Oxytetracycline P.mult_4096 8 4 
FBS MBC Oxytetracycline P.mult_4096 9.6 4.8 
FBS MBC Oxytetracycline P.mult_4096 
 
0 
FBS MIC Oxytetracycline P.mult_4121 8 4 
FBS MIC Oxytetracycline P.mult_4121 7.2 3.6 
FBS MIC Oxytetracycline P.mult_4121 8 4 
FBS MBC Oxytetracycline P.mult_4121 11.2 5.6 
FBS MBC Oxytetracycline P.mult_4121 11.2 5.6 
FBS MBC Oxytetracycline P.mult_4121 11.2 5.6 
FBS MIC Oxytetracycline P.mult_4323 7.2 3.6 
FBS MIC Oxytetracycline P.mult_4323 6.4 3.2 
FBS MIC Oxytetracycline P.mult_4323 5.6 2.8 
FBS MBC Oxytetracycline P.mult_4323 11.2 5.6 
FBS MBC Oxytetracycline P.mult_4323 12.8 6.4 
FBS MBC Oxytetracycline P.mult_4323 12.8 6.4 
FBS MIC Oxytetracycline M.haem_1056 8 4 
FBS MIC Oxytetracycline M.haem_1056 9.6 4.8 
FBS MIC Oxytetracycline M.haem_1056 7.2 3.6 
FBS MBC Oxytetracycline M.haem_1056 9.6 4.8 
FBS MBC Oxytetracycline M.haem_1056 9.6 4.8 
FBS MBC Oxytetracycline M.haem_1056 9.6 4.8 
FBS MIC Oxytetracycline M.haem_1250 4.8 2.4 
FBS MIC Oxytetracycline M.haem_1250 5.6 2.8 
FBS MIC Oxytetracycline M.haem_1250 5.6 2.8 
FBS MBC Oxytetracycline M.haem_1250 8 4 
FBS MBC Oxytetracycline M.haem_1250 9.6 4.8 
FBS MBC Oxytetracycline M.haem_1250 8 4 
FBS MIC Oxytetracycline M.haem_1978 4.8 2.4 
FBS MIC Oxytetracycline M.haem_1978 4.8 2.4 
FBS MIC Oxytetracycline M.haem_1978 5.6 2.8 
FBS MBC Oxytetracycline M.haem_1978 9.6 4.8 
FBS MBC Oxytetracycline M.haem_1978 9.6 4.8 
FBS MBC Oxytetracycline M.haem_1978 6.4 3.2 
FBS MIC Oxytetracycline M.haem_2008 4.8 2.4 
FBS MIC Oxytetracycline M.haem_2008 4 2 
FBS MIC Oxytetracycline M.haem_2008 4.8 2.4 
FBS MBC Oxytetracycline M.haem_2008 12.8 6.4 
FBS MBC Oxytetracycline M.haem_2008 12.8 6.4 
FBS MBC Oxytetracycline M.haem_2008 12.8 6.4 
FBS MIC Oxytetracycline M.haem_2059 4.8 2.4 
FBS MIC Oxytetracycline M.haem_2059 4.8 2.4 
FBS MIC Oxytetracycline M.haem_2059 5.6 2.8 
FBS MBC Oxytetracycline M.haem_2059 8 4 
FBS MBC Oxytetracycline M.haem_2059 7.2 3.6 
FBS MBC Oxytetracycline M.haem_2059 8 4 
FBS MIC Oxytetracycline M.haem_2563 4.8 2.4 
FBS MIC Oxytetracycline M.haem_2563 5.6 2.8 
FBS MIC Oxytetracycline M.haem_2563 4 2 
FBS MBC Oxytetracycline M.haem_2563 19.2 9.6 
FBS MBC Oxytetracycline M.haem_2563 14.4 7.2 
FBS MBC Oxytetracycline M.haem_2563 12.8 6.4 
FBS MIC Tetracycline P.mult_3722 2.8 1.904 
FBS MIC Tetracycline P.mult_3722 2.8 1.904 
FBS MIC Tetracycline P.mult_3722 2.8 1.904 
FBS MBC Tetracycline P.mult_3722 4.8 3.264 
FBS MBC Tetracycline P.mult_3722 4 2.72 
FBS MBC Tetracycline P.mult_3722 4 2.72 
FBS MIC Tetracycline P.mult_3920 2.8 1.904 
FBS MIC Tetracycline P.mult_3920 2.8 1.904 
FBS MIC Tetracycline P.mult_3920 3.2 2.176 
FBS MBC Tetracycline P.mult_3920 5.6 3.808 
FBS MBC Tetracycline P.mult_3920 5.6 3.808 
FBS MBC Tetracycline P.mult_3920 
 
0 
FBS MIC Tetracycline P.mult_4072 1.4 0.952 
FBS MIC Tetracycline P.mult_4072 1.4 0.952 
FBS MIC Tetracycline P.mult_4072 1.8 1.224 
FBS MBC Tetracycline P.mult_4072 8 5.44 
FBS MBC Tetracycline P.mult_4072 7.2 4.896 
FBS MBC Tetracycline P.mult_4072 7.2 4.896 
FBS MIC Tetracycline P.mult_4096 4 2.72 
FBS MIC Tetracycline P.mult_4096 4.8 3.264 
FBS MIC Tetracycline P.mult_4096 5.6 3.808 
FBS MBC Tetracycline P.mult_4096 5.6 3.808 
FBS MBC Tetracycline P.mult_4096 7.2 4.896 
FBS MBC Tetracycline P.mult_4096 9.6 6.528 
FBS MIC Tetracycline P.mult_4121 7.2 4.896 
FBS MIC Tetracycline P.mult_4121 6.4 4.352 
FBS MIC Tetracycline P.mult_4121 7.2 4.896 
FBS MBC Tetracycline P.mult_4121 9.6 6.528 
FBS MBC Tetracycline P.mult_4121 8 5.44 
FBS MBC Tetracycline P.mult_4121 9.6 6.528 
FBS MIC Tetracycline P.mult_4323 5.6 3.808 
FBS MIC Tetracycline P.mult_4323 6.4 4.352 
FBS MIC Tetracycline P.mult_4323 5.6 3.808 
FBS MBC Tetracycline P.mult_4323 11.2 7.616 
FBS MBC Tetracycline P.mult_4323 12.8 8.704 
FBS MBC Tetracycline P.mult_4323 11.2 7.616 
FBS MIC Tetracycline M.haem_1056 9.6 6.528 
FBS MIC Tetracycline M.haem_1056 11.2 7.616 
FBS MIC Tetracycline M.haem_1056 9.6 6.528 
FBS MBC Tetracycline M.haem_1056 11.2 7.616 
FBS MBC Tetracycline M.haem_1056 11.2 7.616 
FBS MBC Tetracycline M.haem_1056 12.8 8.704 
FBS MIC Tetracycline M.haem_1250 7.2 4.896 
FBS MIC Tetracycline M.haem_1250 7.2 4.896 
FBS MIC Tetracycline M.haem_1250 5.6 3.808 
FBS MBC Tetracycline M.haem_1250 9.6 6.528 
FBS MBC Tetracycline M.haem_1250 9.6 6.528 
FBS MBC Tetracycline M.haem_1250 9.6 6.528 
FBS MIC Tetracycline M.haem_1978 9.6 6.528 
FBS MIC Tetracycline M.haem_1978 9.6 6.528 
FBS MIC Tetracycline M.haem_1978 7.2 4.896 
FBS MBC Tetracycline M.haem_1978 
 
0 
FBS MBC Tetracycline M.haem_1978 9.6 6.528 
FBS MBC Tetracycline M.haem_1978 9.6 6.528 
FBS MIC Tetracycline M.haem_2008 7.2 4.896 
FBS MIC Tetracycline M.haem_2008 7.2 4.896 
FBS MIC Tetracycline M.haem_2008 7.2 4.896 
FBS MBC Tetracycline M.haem_2008 28.8 19.584 
FBS MBC Tetracycline M.haem_2008 22.4 15.232 
FBS MBC Tetracycline M.haem_2008 22.4 15.232 
FBS MIC Tetracycline M.haem_2059 8 5.44 
FBS MIC Tetracycline M.haem_2059 9.6 6.528 
FBS MIC Tetracycline M.haem_2059 8 5.44 
FBS MBC Tetracycline M.haem_2059 9.6 6.528 
FBS MBC Tetracycline M.haem_2059 11.2 7.616 
FBS MBC Tetracycline M.haem_2059 11.2 7.616 
FBS MIC Tetracycline M.haem_2563 7.2 4.896 
FBS MIC Tetracycline M.haem_2563 8 5.44 
FBS MIC Tetracycline M.haem_2563 5.6 3.808 
FBS MBC Tetracycline M.haem_2563 32 21.76 
FBS MBC Tetracycline M.haem_2563 22.4 15.232 
FBS MBC Tetracycline M.haem_2563 16 10.88 
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